REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2021

Aug 27, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS, INC. (REGN)
CIK: 0000872589
Period of Report: 2021-08-25

Reporting Person: VAGELOS P ROY (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-25	Common Stock	M	75000	$179.13	Acquired	366090	Direct
2021-08-25	Common Stock	F	49282	$667.39	Disposed	316808	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-08-25	Non-Qualified Stock Option (right to buy)	$179.13	M	75000	Disposed	2022-12-14	Common Stock (75000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2218	Indirect
Common Stock	141977	Indirect
Common Stock	37747	Indirect
Common Stock	3609	Indirect

Footnotes

F1: By trusts for the benefit of nine grandchildren of the reporting person, each of which holds 401 shares of Company stock. The reporting person and/or the spouse of the reporting person is the trustee of each such trust.

F2: The stock option award vests in four equal annual installments, commencing one year after the date of grant.